Heron Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative product candidates to address unmet medical needs in the treatment of various pain conditions and supportive care for patients undergoing chemotherapy. The company's expertise lies in harnessing proprietary formulations and delivery technologies to improve the efficacy and safety of existing therapies, thereby enhancing the overall patient experience. Heron Therapeutics is dedicated to advancing its pipeline of novel therapeutics aimed at providing effective solutions for managing acute pain and chemotherapy-induced nausea and vomiting, striving to improve the quality of life for patients.
Heron Therapeutics' Q4 2023 results: Beat EPS consensus at $(0.07), $34.23 million sales, up 14% Y/Y. Strong momentum in acute and oncology care franchises. Fiscal year 2024 guidance: $138 million-$158 million revenue, with positive adjusted EBITDA.
Shares of BlackBerry Limited (NYSEBB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes. BlackBerry shares tumbled 17.2% to $2.9387 on Wednesday.
Shares of Clover Health Investments, Corp. (NASDAQCLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24 insurance revenue guidance.
Zynrelef's expanded FDA approval for soft tissue and orthopedic surgeries, offering superior pain management with lower pain scores and opioid consumption.
U.S. stocks traded higher, with the Nasdaq Composite gaining around 100 points on Wednesday. Shares of Textron Inc. (NYSETXT) rose during Wednesday’s session following upbeat quarterly earnings.
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 100 points on Tuesday. Shares of Hewlett Packard Enterprise Company (NYSEHPE) shares fell sharply in pre-market trading on Tuesday.
Shares of LumiraDx Limited (NASDAQLMDX) shares fell sharply in pre-market trading. LumiraDx announced its securities will be suspended from trading on Nasdaq at the open of business on Jan. 9th. LumiraDx shares dipped 30.5% to $0.0239 in pre-market trading.
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 150 points on Monday. Shares of Harpoon Therapeutics, Inc.(NASDAQHARP) rose sharply in pre-market trading. Bloomberg reported that Merck is in advanced talks to buy Harpoon Therapeutics for $23 per share.
